Apr
14

What is BHRT and 5 ways it Could Benefit Your Patients

What is BHRT and 5 ways it Could Benefit Your Patients Written by Krista Russ Previously, we discussed how patients are taking more medications and experiencing an endless conundrum of health issues. The systemic failure to address the root causes of disease is a huge part of the problem. Along with the proven benefits of
DETAIL
Feb
08

Treating T3 Deficiency: Thyroid Optimization

By Neal Rouzier, MD High Dose Replacement with thyroid hormone DOES NOT cause harm as demonstrated in interventional studies. The harm of Graves’ disease should not be extrapolated to optimal replacement. Understanding the controversies of thyroid hormone levels and thyroid hormone replacement-that which AACE and your peers do not understand or realize. The last webinar
DETAIL
Jan
11

Treating T3 Deficiency: The Most Important of the Thyroid Webinars So Far

By Neal Rouzier, MD CASE: Your hormonally optimized 45 y/o female patient requests an office visit to discuss her thyroid hormone. Her PMD chastises her for taking thyroid hormone and states that he does not wish to see her anymore as a patient. She relates that upon routine testing of thyroid function, that the TSH
DETAIL
Sep
27

How to Protect Against Collateral Damage

By Neal Rouzier, MD This is the last and final newsletter before the upcoming Hormones and Beyond 2021. I hope that you have enjoyed the commentary of these newsletters. They are an introduction as to what will be presented at Hormones and Beyond in 2 weeks. My primary focus on Friday will address reversal of
By Deirdre Nitsche | Blog . CVD
DETAIL
Sep
23

PCSK-9 Inhibitors : Another Therapeutic Illusion

By Neal Rouzier, MD Recently, a new cholesterol lowering drug was approved in the U.K. The press-release heralded Inclisiran, simply another PCSK-9 inhibitor, to be a game changer as it will save thousands of lives by lowering cholesterol. No, there are no outcome studies yet, only studies that demonstrate it lowers serum cholesterol 50% more
By Deirdre Nitsche | Blog . CVD
DETAIL
Aug
06

Treating T3 Deficiency: Recent Literature Supports That Low Free T3 was the Highest Independent Predictor of Death in CV Patients

Recommended Pre-Reading: Treating T3 Deficiency, The Evidence You Need Interested in monthly webinars? Upgrade your Membership SCENARIO: A 59 y/o female with CVD is referred by her friend for evaluation of hypothyroidism. Laboratory tests consistently show a mildly elevated TSH and normal Free T4. Despite multiple attempts to try to get her PMD to prescribe a trial
By Deirdre Nitsche | Blog . CVD . Disease . HRT Evidence Based Literature . Thyroid
DETAIL
Jul
29

Treating T3 Deficiency: More Proof and Reasoning that T4 Monotherapy Results in Inadequate Conversion and FINALLY the AACE releases a revised statement on Thyroid Treatment

Recommended Pre-Reading: Treating T3 Deficiency: If T4 Does not Improve Symptoms, and Normalizing TSH Does not Guarantee or Infer Improvement in Symptoms, Then How Should we Treat Patients? SCENARIO: A 45 y/o female with persistent symptoms of fatigue, low energy, depression, presents for evaluation of her thyroid hormone therapy. She is referred by her friend
DETAIL
Jul
27

Treating T3 Deficiency: If T4 Does not Improve Symptoms, and Normalizing TSH Does not Guarantee or Infer Improvement in Symptoms, Then How Should we Treat Patients?

Recommended Pre-Reading: Treating T3 Deficiency, The Evidence You Need SCENARIO: Your 41 y/o PCOS patient that is optimized on thyroid returns with concerns that her PMD does not like/approve of DTE. She notes that she is finally feeling well and experiencing success with weight loss. The PMD also is upset with the suppressed TSH level
DETAIL
Jul
26

CVD: Could all the Medicines that we Prescribe, Including Statins, be Increasing the Risk of Cancer?

By Neal Rouzier, MD CVD is the # 1 killer in the U.S. and worldwide. The medical literature and pharmaceutical industry has led us to believe in the cholesterol-centric model in preventing CVD. Unfortunately, utilizing cholesterol-lowering medication has only led to a 1-3% absolute risk reduction (ARR) in CVD and mortality. Not very impressive for all
By Deirdre Nitsche | Blog . CVD
DETAIL
Jul
14

The CVD and Cancer Insanity Cycle : What Should we do if What we are Doing Isn’t Working?

By Neal Rouzier, MD As clinicians we try to be problem solvers. It is part of our training, try to figure out what’s wrong, and then to fix it. Problem solved. However, what should we do if what we are doing isn’t working? Keep doing the same thing? What if the patient does not get better?
By Deirdre Nitsche | Blog . Cancer . CVD
DETAIL